Lal S M, Gupta N, Georgiev O, Ross G
Department of Internal Medicine, University of Missouri-Columbia Health Sciences Center, USA.
Int J Artif Organs. 1997 Jan;20(1):18-21.
A Atherosclerosis-related cardiovascular disease remains an important cause of morbidity and mortality in renal transplant patients. We assessed the efficacy and safety of the newer synthetic HMG-CoA reductase inhibitor, fluvastatin, in 12 renal transplant patients who remained hypercholesterolemic, despite having been on the American Heart Association (AHA) Step I diet for 6 weeks. At 8 weeks, compared to the control phase, fluvastatin therapy, 20 mg/day, reduced the total cholesterol (TC) from 321 +/- 57 [+/-SD] to 301 +/- 123 mg/dl (p = 0.3); low-density lipoprotein cholesterol (LDL-C), from 209 +/- 56 to 176 +/- 81 mg/dl (p = 0.2); and the triglyceride (TG) levels from 343 +/- 119 to 277 +/- 117 mg/dl (p = 0.06); all these changes were statistically insignificant. However, the therapy significantly increased the high-density lipoprotein cholesterol (HDL-C) from 37 +/- 11 to 46 +/- 13 mg/dl (p = 0.006). During this short-term treatment period no adverse biochemical effects were noted with the therapy.
动脉粥样硬化相关的心血管疾病仍然是肾移植患者发病和死亡的重要原因。我们评估了新型合成HMG-CoA还原酶抑制剂氟伐他汀对12例肾移植患者的疗效和安全性，这些患者尽管已遵循美国心脏协会（AHA）一级饮食6周，但仍存在高胆固醇血症。在8周时，与对照阶段相比，氟伐他汀20毫克/天的治疗使总胆固醇（TC）从321±57[±标准差]降至301±123毫克/分升（p = 0.3）；低密度脂蛋白胆固醇（LDL-C）从209±56降至176±81毫克/分升（p = 0.2）；甘油三酯（TG）水平从343±119降至277±117毫克/分升（p = 0.06）；所有这些变化均无统计学意义。然而，该治疗使高密度脂蛋白胆固醇（HDL-C）从37±11显著增加至46±13毫克/分升（p = 0.006）。在这个短期治疗期间，未观察到该治疗有不良生化影响。
